| WARF: P01381US |  |
| 1Alpha-Hydroxy-2-Methylene-19-Nor-Homopregnacalciferol and Its Potential Therapeutic Uses |
| INVENTORS | • | Hector DeLuca, Rafal Sicinski, Sumithra Gowlugari, Lori Plum, Margaret Clagett-Dame |
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a 19-nor-1alpha,25-dihydroxyvitamin D analog that may be useful in the treatment of several disorders.
OVERVIEW
Vitamin D is a highly potent regulator of calcium homeostasis and plays an established role in cellular differentiation. A recently discovered class of vitamin D analogs, the 19-nor-vitamin D compounds, displays a selective activity profile of high cellular differentiation activity but very low calcium mobilizing activity. This profile makes these compounds potentially useful treatments for various disorders.
THE INVENTION
UW-Madison researchers have developed a vitamin D analog, known as 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol. This compound, a 19-nor-1alpha,25-dihydroxyvitamin D analog, is characterized by a hydroxyl group at carbon 1, a methylene substituent at carbon 2, and a shortened side chain attached to carbon 20. Compared to 1alpha,25-dihydroxyvitamin D3, it exhibits relatively high binding to vitamin D receptors, very low intestinal calcium transport activity, and very low tendency to mobilize calcium from bone. This compound is characterized by relatively high cell differentiation activity, suggesting its use as an anti-cancer agent or a therapeutic agent for treating skin conditions. In addition, it suppresses production of parathyroid hormone, making it an ideal candidate for treatment of renal osteodystrophy.
APPLICATIONS
- Potential anti-cancer agent, especially against leukemia, colon cancer, breast cancer and prostate cancer
- May be useful for the treatment of skin diseases, such as psoriasis, as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion
- Potential for treating immune disorders in humans including multiple sclerosis, lupis, diabetes mellitus, host versus graft reaction and organ transplant rejection
- Prospective treatment for inflammatory diseases such as rheumatoid arthritis, asthma and inflammatory bowel diseases
- May also be used to hasten bone fracture healing and improve bone grafts
- Promising treatment for renal osteodystrophy
- May be used to treat other disorders including acne, alopecia and hypertension
KEY BENEFITS
- Potentially useful for the treatment of various disorders
- Compound may be administered topically, transdermally, orally or parenterally.
ADDITIONAL INFORMATION
For More Information About the Inventors
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Skin & connective tissue
Pharmaceuticals & Vitamin D - Vitamin D
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF: A Leader in Technology Transfer Since 1925
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
